As an effector of oncogenic Gαq-Q209L, PDZ-RhoGEF might constitute a protumoral signaling hub linked to the cytoskeletal effects driven by RhoJ, which is involved in tumor-induced angiogenesis, metastatic dissemination of cancer cells, and resistance to anti-cancer therapies in cells undergoing epithelial mesenchymal transition [14,15,16,18]. The gene discussed is RHOJ; the disease is cancer.